Novartis receives FDA approval for eye drop solution

WASHINGTON - Feb. 3, 2015 - PRLog -- Novartis’ eye care division, Alcon received approval from the U.S. Food and Drug Administration (FDA) for their ophthalmic solution Pazeo 0.7% to treat ocular itching associated with allergic conjunctivitis. Allergies of this nature affect up to 70%- 80% of the U.S population during the allergy season. "Allergic conjunctivitis (eye allergies) can be a 24-hour-a-day burden for patients suffering from those symptoms," said Eric Donnenfeld, MD, founding partner of Ophthalmic Consultants of Long Island and clinical professor of ophthalmology at New York University. "Patients now have an available option that can provide ocular itch relief with efficacy demonstrated at 24 hours. This approval represents an exciting new option in ocular allergy itch relief therapy."

Pazeo was successful in alleviating eye itching at 24 hours post-treatment compared to olopatadine 0.2% (known as Pataday®solution) according to the results from two Conjunctival Allergen Challenge clinical studies. Pazeo also had a comparable safety profile to that of olopatadine 0.2%.

"Pazeo solution represents an important addition to our ocular allergy portfolio in the United States," said Sabri Markabi, Senior Vice President, Research & Development for Alcon. "Patients who experience itching due to allergic conjunctivitis (eye allergies), will now be able to turn to a one-drop daily product with efficacy data 24 hours after dosing."

Pazeo is expected to be available in the United States by March 2015, followed by launches in the Latin American and Asian markets through 2017.

With such industry leaders paving the way with new, beneficial therapeutic breakthroughs, they will need both certified and qualified individuals to promote their diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to sell their product both proficiently and efficiently. The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/